Many patients don't reach target dose of atomoxetine

August 11, 2016

(HealthDay)—A considerable proportion of patients receiving atomoxetine (ATX), especially those receiving ATX monotherapy, do not reach the recommended dose of 80 mg/day (ATX ≥80), according to a study published online July 31 in CNS Neuroscience & Therapeutics.

David B. Clemow, Ph.D., from Lilly USA in Indianapolis, and colleagues conducted a retrospective observational cohort study involving adults with attention-deficit/hyperactivity disorder (ADHD). In patients prescribed ATX monotherapy (mono; 36,076 patients) and ATX in combination with other ADHD medications (combo; 1,548 patients), the authors compared ATX length of therapy (LoT) among those who reached the recommended dose (ATX ≥80) versus those who did not (ATX <80).

The researchers found that at one-year follow-up, 45.0 and 77.9 percent of the patients in the mono and combo groups, respectively, reached the recommended dose. Over the course of a year, the total days of therapy were significantly higher for patients who filled at least one 80-mg prescription versus those who did not (P < 0.0001). Combo patients had longer ATX LoT, irrespective of whether they reached 80 mg/day ATX or not (P < 0.0001). For mono patients, LoT was 93.8 days longer for ATX ≥80 versus ATX <80.

"Ensuring adult ADHD patients are treated with ATX at a target dose of 80 mg/day is an important clinical consideration for maximizing patient days on therapy, which can be important for treatment optimization," the authors write.

The study was funded by Lilly, the manufacturer of atomoxetine

Explore further: No need for more propofol for MRI sedation in ADHD

More information: Abstract
Full Text

Related Stories

No need for more propofol for MRI sedation in ADHD

July 25, 2015

(HealthDay)—Children with attention-deficit/hyperactivity disorder (ADHD) undergoing sedation for magnetic resonance imaging (MRI) do not have a higher dose requirement for propofol, according to a study published online ...

Increase in evidence-based practice for children with ADHD

August 4, 2016

(HealthDay)—More Medicaid-covered children are receiving treatments that conform to practice standards for attention-deficit/hyperactivity disorder (ADHD), including the use of combined medication and psychotherapy, according ...

ADHD or just immature?

March 10, 2016

Attention-deficit hyperactivity disorder (ADHD) is typically diagnosed in childhood and manifests as an inability to sustain attention and control activity levels and impulse control. Some reports have indicated a prevalence ...

Recommended for you

Unhealthy diet during pregnancy could be linked to ADHD

August 18, 2016

New research led by scientists from King's College London and the University of Bristol has found that a high-fat, high-sugar diet during pregnancy may be linked to symptoms of ADHD in children who show conduct problems early ...

Epilepsy may triple ADHD risk, Danish study finds

July 13, 2016

(HealthDay)—Children who suffer from epilepsy or fever-related seizures may face a higher risk of also having attention-deficit/hyperactivity disorder (ADHD), new Danish research suggests.

Exercise may help ease adult ADHD symptoms

July 6, 2016

(HealthDay)—A burst of moderate exercise may improve motivation and energy in adults with symptoms of attention deficit hyperactivity disorder (ADHD), a small new study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.